Publications by authors named "Moritz Meyer-Jens"
Sacubitril/valsartan (Sac/Val) belongs to the group of angiotensin receptor-neprilysin inhibitors and has been used for the treatment of heart failure (HF) for several years. The mechanisms that mediate the beneficial effects of Sac/Val are not yet fully understood. In this study we investigated whether Sac/Val influences the two proteolytic systems, the ubiquitin-proteasome system (UPS) and the autophagy-lysosomal pathway (ALP), in a mouse model of pressure overload induced by transverse aortic constriction (TAC) and in human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) treated with endothelin-1 (ET1) serving as a human cellular model of hypertrophy.
View Article and Find Full Text PDFArticle Synopsis
- The study investigates the effects of a missense genetic variant in the ACTN2 gene, linked to various forms of cardiomyopathy, particularly hypertrophic cardiomyopathy.
- Using CRISPR/Cas9, researchers created two types of human stem cell-derived cardiomyocyte lines to compare the normal and mutated ACTN2 genes.
- Results showed that the mutated ACTN2 led to structural and functional issues in cardiomyocytes, including increased multinucleation and protein aggregation, and activated proteolytic systems to manage these problems, suggesting a link to cardiac diseases.
The ubiquitin-proteasome system (UPS) and autophagy-lysosomal pathway (ALP) are two major protein degradation pathways in eukaryotic cells. Initially considered as two independent pathways, there is emerging evidence that they can work in concert. As alterations of UPS and ALP function can contribute to neurodegenerative disorders, cancer and cardiac disease, there is great interest in finding targets that modulate these catabolic processes.
View Article and Find Full Text PDF